{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T09:47:35Z","timestamp":1793785655760,"version":"4.6.1"},"reference-count":33,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T00:00:00Z","timestamp":1748390400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008897","name":"janssen Pharmaceutica NV","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceutica","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Fundaci\u00f3n CRIS contra el c\u00e1ncer"}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.annonc.2025.05.534","type":"journal-article","created":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T11:08:19Z","timestamp":1748862499000},"page":"1190-1202","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"title":["BRCA1\/2 and homologous recombination repair alterations in high- and low-volume metastatic hormone-sensitive prostate cancer: prevalence and impact on outcomes"],"prefix":"10.1016","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7003-4826","authenticated-orcid":false,"given":"D.","family":"Olmos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7550-0657","authenticated-orcid":false,"given":"D.","family":"Lorente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Jambrina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1707-0702","authenticated-orcid":false,"given":"D.","family":"Tello-Velasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1328-9491","authenticated-orcid":false,"given":"M.","family":"Ovejero-S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3693-9957","authenticated-orcid":false,"given":"I.","family":"Gonzalez-Ginel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8715-8860","authenticated-orcid":false,"given":"N.","family":"Romero-Laorden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5910-2018","authenticated-orcid":false,"given":"D.","family":"Nunes-Carneiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Balongo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.M.","family":"Gutierrez-Pecharrom\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4107-5522","authenticated-orcid":false,"given":"C.","family":"Ll\u00e1cer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4070-1181","authenticated-orcid":false,"given":"J.D.","family":"Prieto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-2031-8166","authenticated-orcid":false,"given":"D.","family":"P\u00e9rez-Arg\u00fcelles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Alberca del Arco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Miguel-Masi\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5638-0634","authenticated-orcid":false,"given":"M.","family":"Ruiz-Vico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2547-016X","authenticated-orcid":false,"given":"J.","family":"Esteban-Villarrubia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Gonzalez-Billalabeitia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"J\u00fcrgens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Capone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9578-0171","authenticated-orcid":false,"given":"M.","family":"Trevisan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Van Sanden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Stulnig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9866-7361","authenticated-orcid":false,"given":"P.P.","family":"L\u00f3pez-Casas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7841-708X","authenticated-orcid":false,"given":"A.","family":"Rodriguez-Antolin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.E.","family":"Castellano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Herrera-Imbroda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"16","key":"10.1016\/j.annonc.2025.05.534_bib1","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1001\/jama.2025.0228","article-title":"Prostate cancer: a review","volume":"333","author":"Raychaudhuri","year":"2025","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.annonc.2025.05.534_bib2","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"N Engl J Med"},{"issue":"10024","key":"10.1016\/j.annonc.2025.05.534_bib3","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","article-title":"Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial","volume":"387","author":"James","year":"2016","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.annonc.2025.05.534_bib4","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer","volume":"377","author":"Fizazi","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.annonc.2025.05.534_bib5","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1903307","article-title":"Apalutamide for metastatic, castration-sensitive prostate cancer","volume":"381","author":"Chi","year":"2019","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.annonc.2025.05.534_bib6","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1200\/JCO.22.00193","article-title":"Improved survival with enzalutamide in patients with metastatic hormone-sensitive prostate cancer","volume":"40","author":"Armstrong","year":"2022","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.annonc.2025.05.534_bib7","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1056\/NEJMoa1903835","article-title":"Enzalutamide with standard first-line therapy in metastatic prostate cancer","volume":"381","author":"Davis","year":"2019","journal-title":"N Engl J Med"},{"issue":"10336","key":"10.1016\/j.annonc.2025.05.534_bib8","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","article-title":"Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 \u00d7 2 factorial design","volume":"399","author":"Fizazi","year":"2022","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.annonc.2025.05.534_bib9","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","article-title":"Darolutamide and survival in metastatic, hormone-sensitive prostate cancer","volume":"386","author":"Smith","year":"2022","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.annonc.2025.05.534_bib10","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1002\/pros.23645","article-title":"Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC)","volume":"78","author":"Francini","year":"2018","journal-title":"Prostate"},{"issue":"13","key":"10.1016\/j.annonc.2025.05.534_bib11","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1158\/1078-0432.CCR-20-0168","article-title":"Oncogenic genomic alterations, clinical phenotypes, and outcomes in metastatic castration-sensitive prostate cancer","volume":"26","author":"Stopsack","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annonc.2025.05.534_bib12","article-title":"Prospective genomic profiling of prostate cancer across disease states reveals germline and somatic alterations that may affect clinical decision making","volume":"2017","author":"Abida","year":"2017","journal-title":"JCO Precis Oncol"},{"issue":"suppl 2","key":"10.1016\/j.annonc.2025.05.534_bib13","article-title":"1835P A prospective study to determine the prevalence of DNA repair defects in patients (pts) with advanced prostate cancer (PC)","volume":"34","author":"Sandhu","year":"2023","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.annonc.2025.05.534_bib14","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.eururo.2016.08.037","article-title":"DNA repair in prostate cancer: biology and clinical implications","volume":"71","author":"Mateo","year":"2017","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.annonc.2025.05.534_bib15","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.clgc.2022.06.016","article-title":"The prognostic significance of homologous recombination repair pathway alterations in metastatic hormone sensitive prostate cancer","volume":"20","author":"Lee","year":"2022","journal-title":"Clin Genitourin Cancer"},{"issue":"1","key":"10.1016\/j.annonc.2025.05.534_bib16","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/bju.16462","article-title":"Impact of homologous recombination repair\/BReast CAncer (BRCA) gene alterations on survival in a real-world setting of metastatic prostate cancer","volume":"135","author":"Wenzel","year":"2025","journal-title":"BJU Int"},{"key":"10.1016\/j.annonc.2025.05.534_bib17","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.annonc.2024.01.011","article-title":"Treatment patterns and outcomes in metastatic castration-resistant prostate cancer patients with and without somatic or germline alterations in homologous recombination repair genes","volume":"35","author":"Olmos","year":"2024","journal-title":"Ann Oncol"},{"issue":"14","key":"10.1016\/j.annonc.2025.05.534_bib18","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1200\/JCO.2012.43.1882","article-title":"Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer","volume":"31","author":"Castro","year":"2013","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.annonc.2025.05.534_bib19","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.eururo.2018.01.035","article-title":"Germline DNA-repair gene mutations and outcomes in men with metastatic castration-resistant prostate cancer receiving first-line abiraterone and enzalutamide","volume":"74","author":"Antonarakis","year":"2018","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.annonc.2025.05.534_bib20","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1200\/JCO.18.00358","article-title":"PROREPAIR-B: a prospective cohort study of the impact of germline DNA repair mutations on the outcomes of patients with metastatic castration-resistant prostate cancer","volume":"37","author":"Castro","year":"2019","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2025.05.534_bib21","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/s41591-023-02704-x","article-title":"First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial","volume":"30","author":"Fizazi","year":"2024","journal-title":"Nat Med"},{"issue":"10398","key":"10.1016\/j.annonc.2025.05.534_bib22","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0140-6736(23)01055-3","article-title":"Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial","volume":"402","author":"Agarwal","year":"2023","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.annonc.2025.05.534_bib23","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1056\/NEJMoa2214676","article-title":"Rucaparib or physician\u2019s choice in metastatic prostate cancer","volume":"388","author":"Fizazi","year":"2023","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.annonc.2025.05.534_bib24","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1056\/NEJMoa2022485","article-title":"Survival with olaparib in metastatic castration-resistant prostate cancer","volume":"383","author":"Hussain","year":"2020","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.annonc.2025.05.534_bib25","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.annonc.2023.06.009","article-title":"Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial","volume":"34","author":"Chi","year":"2023","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.annonc.2025.05.534_bib26","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.euo.2024.09.013","volume":"8","author":"Clarke","year":"2025","journal-title":"Eur Urol Oncol"},{"issue":"4","key":"10.1016\/j.annonc.2025.05.534_bib27","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.eururo.2018.12.042","article-title":"Circulating tumor DNA abundance and potential utility in de novo metastatic prostate cancer","volume":"75","author":"Vandekerkhove","year":"2019","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.annonc.2025.05.534_bib28","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1093\/annonc\/mdy072","article-title":"Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol","volume":"29","author":"Sydes","year":"2018","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.annonc.2025.05.534_bib29","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1016\/j.annonc.2020.06.006","article-title":"HSD3B1 (1245A>C) germline variant and clinical outcomes in metastatic castration-resistant prostate cancer patients treated with abiraterone and enzalutamide: results from two prospective studies","volume":"31","author":"Khalaf","year":"2020","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.annonc.2025.05.534_bib30","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.eururo.2020.02.025","article-title":"Association between second progression-free survival (PFS2) and overall survival in metastatic castration-resistant prostate cancer","volume":"77","author":"Lorente","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.annonc.2025.05.534_bib31","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ejca.2023.02.022","article-title":"Impact of concurrent tumour events on the prostate cancer outcomes of germline BRCA2 mutation carriers","volume":"185","author":"Lozano","year":"2023","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.annonc.2025.05.534_bib32","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.euo.2023.09.015","article-title":"Prospective assessment of bone metabolism biomarkers and survival in metastatic castration-resistant prostate cancer patients treated with radium-223: the PRORADIUM study","volume":"7","author":"Romero-Laorden","year":"2024","journal-title":"Eur Urol Oncol"},{"issue":"9","key":"10.1016\/j.annonc.2025.05.534_bib33","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.3390\/cancers11091355","article-title":"Current treatment options for metastatic hormone-sensitive prostate cancer","volume":"11","author":"Cattrini","year":"2019","journal-title":"Cancers (Basel)"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753425007392?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753425007392?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T05:14:33Z","timestamp":1762319673000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753425007392"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":33,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S0923753425007392"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2025.05.534","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"BRCA1\/2 and homologous recombination repair alterations in high- and low-volume metastatic hormone-sensitive prostate cancer: prevalence and impact on outcomes","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2025.05.534","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}]}}